Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

58.58 -2.54 (-4.16%)
Official Closing Price Updated: 6:30 PM EDT, May 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
22 23 Next >
2 Telehealth Stocks That Could Gain from Trump’s New FDA Pick
Discover two telehealth stocks, Hims & Hers (HIMS) and Teladoc (TDOC), poised to benefit from Trump's FDA nominee, Dr. Marty Makary, a telemedicine advocate. 
Via MarketBeat
Topics Government Lawsuit
Exposures Financial Legal Political
The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market
An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in obesity. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Where Hims & Hers Health Stands With Analysts
Via Benzinga
Exploring growth characteristics of HIMS & HERS HEALTH INC (NYSE:HIMS).
Should you consider HIMS & HERS HEALTH INC (NYSE:HIMS) for growth investing? 
Via Chartmill
Spotlight on Hims & Hers Health: Analyzing the Surge in Options Activity
Via Benzinga
Unpacking the Latest Options Trading Trends in Hims & Hers Health
Via Benzinga
Price Over Earnings Overview: Hims & Hers Health
Via Benzinga
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
8 mid-cap stocks saw impressive gains last week. Archer, Scholar Rock, Arrowhead, Iris Energy, Hims & Hers, SoundHound, Joby Aviation, and Urban Outfitters all performed well. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
Here's why Eli Lilly, Pfizer, and AstraZeneca are biotech stocks worth considering, with strong pipelines and growth potential beyond vaccines. 
Via MarketBeat
Topics Government
Exposures COVID-19 Political Product Safety
Why Hims & Hers Stock Jumped on Massive FDA News
Shares of Hims & Hers were on fire Monday because the FDA's new leader seems to be a fan of the company's business model. 
Via The Motley Fool
Exposures Product Safety
Should You Buy Hims & Hers Stock on the Dip?
Via The Motley Fool
Peering Into Hims & Hers Health's Recent Short Interest
Via Benzinga
Unpacking the Latest Options Trading Trends in Hims & Hers Health
Via Benzinga
Technical Monday: A Fresh Look At The “Vanity” Trade
Nu Skin is an American multi-level marketing company for personal care products and dietary supplements. 
Via Talk Markets
Topics ETFs Stocks / Equities
What's Going On With Hims & Hers Health Stock Monday?
Shares of Hims & Hers Health, Inc. (NYSE: HIMS) traded higher on Monday in response to President-elect Donald Trump's plans to nominate Marty Makary to lead the Food and Drug Administration (FDA).... 
Via Benzinga
Topics Government
Exposures Political
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday
Via Benzinga
Applied Digital And Hims & Hers Health Are Among Top 9 Mid-Cap Gainers Last Week (Nov 18-Nov 22): Are The Others In Your Portfolio?
The top performers in the last week were Lemonade, Inc., Archer Aviation Inc., C3.ai, Inc., Oklo Inc., Applied Digital Corporation, Unity Software Inc., Nebius Group N.V., NuScale Power Corporation,... 
Via Benzinga
Hims & Hers New Growth Category Is a Huge Surprise
Is the food business the right business for Hims & Hers to be in? 
Via The Motley Fool
Amazon Sets Sights on Both Hims & Hers and Temu. Is This a Golden Opportunity to Buy the Stock?
Via The Motley Fool
Guardant Health Stock Sees RS Rating Jump To 83
On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. 
Via Investor's Business Daily
Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 16
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Nov. 11-15, 2024. 
Via Talk Markets
Hims & Hers Stock Is Down 30% This Week: Here's What Happened
Hims & Hers has given back recent gains, but don't overlook the company's massive growth. 
Via The Motley Fool
From Volatility To Opportunity: Key Stocks Poised To Shine Today
Volatile market? Learn how RCAT, ROOT, and GEO stand out with robust catalysts, sentiment, and fundamentals. 
Via Talk Markets
Hims & Hers Health Stock Is Tumbling Thursday: What's Going On?
Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower in possible response to Amazon.com Inc's (NASDAQ:AMZN) new upfront pricing for telehealth visits and treatment plans. 
Via Benzinga
What's Going On With Hims & Hers Health Stock On Wednesday?
Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing rising demand and pharmacy shortages. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Up 298% in a Year, Is Hims & Hers Health Still a Buy?
The healthcare company is on fire, and it's still cheap by many measures. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback